Publish date: 29 April 2026
A clinical trial held at Blackpool Teaching Hospitals has shown promising results for patients suffering from myeloma.
The trial, named MajesTEC-3, attracted the highest number of participants in the UK and was open to adults with recurring or treatment-resistant multiple myeloma. Myeloma is a cancer which affects the blood and the bone marrow.
The trial involved participants receiving a new combination of immunotherapy drugs, a type of treatment that uses the body’s own immune system to fight disease such as cancer, by helping it recognise and attack harmful cells.
These were combined with established treatments, aiming to enhance the immune system’s ability to control the cancer.
The results demonstrated a number of improvements for patients receiving the two immunotherapy drugs, including:
- Over 81% of patients achieved a complete response to treatment
- Higher indications of remission (a decrease or disappearance of a disease's signs and symptoms) was noted
Participation in MajesTEC‑3 meant that patients at Blackpool had early access to a highly effective, off‑the‑shelf immunotherapy, with close monitoring and expert support from experienced research nurses and clinicians. This has contributed directly to evidence that is changing how myeloma is treated worldwide
The trial was led locally by Principal Investigator and Blackpool Teaching Hospitals Consultant Haematologist, Dr Mark Grey, who praised the collective effort across the Trust.
He said: “For Blackpool to be the highest recruiter in the UK for a trial like MajesTEC‑3, which has some practice‑changing results for patients with myeloma, is a testament to just how good the Blackpool haematology trials team and the whole trials unit are.
“Trials like this would also not be possible without the support of fantastic staff working across the haematology department on the ward, ambulatory and day case units and in the clinics.”
